ImmunoTargets and Therapy

Immune Targets and Novel Therapies for Systemic Lupus Erythematosus and Related Disorders

Systemic lupus erythematosus (SLE) is a prototype systemic autoimmune disease that mainly affects the younger population. Despite newer immunomodulatory therapies, the survival of the disease fails to improve since the mid-1990s. Early diagnosis and recognition of disease activity, and the use of more aggressive therapies for high-risk patients is the key to reduce disease flares, organ damage and improve quality of life. There is an unmet need to develop novel therapies with a better therapeutic index in patients suffering from SLE and related diseases such as Sjogren’s disease, undifferentiated connective tissue disease (UCTD) and systemic sclerosis.